Can Ionis Pharmaceuticals Become a Biotech Powerhouse?
Ionis Pharmaceuticals has been quietly building its commercial pipeline, and recent developments suggest that the company might be on the cusp of transitioning into an independent biotech powerhouse.
However, beneath this success lies a more complex picture. The company's latest financial report shows remarkable revenue generation, with total sales reaching $268 million in Q2 2026.